Change in taste · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐related quality of life · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
1 finding from 1 review
Change in sense of smell · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
3 findings from 1 review
no estimate extracted
1 study · 77 participants
Very low
no estimate extracted
1 study · 100 participants
Very low
no estimate extracted
1 study · 77 participants
Low
Change in taste · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐related quality of life · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Heart failure · adults with cancer receiving anthracyclines
Dexrazoxane probably leads to lower clinical heart failure Available case analysis compared with no cardioprotective intervention or placebo (moderate certainty).
1 finding from 1 review
Secondary malignant neoplasms · adults with cancer receiving anthracyclines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Heart failure · children with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in clinical heart failure Available‐case analysis compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Cardiomyopathy/heart failure primary cause of death Available‐case analysis · children with cancer receiving anthracyclines
1 finding from 1 review
Clinical heart failure and subclinical myocardial dysfunction combined Defined as (1) evidence of clinical congestive heart failure, (2) a reduction in LVEF as measured by MUGA to < 45% or (3) a decrease in LVEF as measured by MUGA of > 20 percent... · children with cancer receiving anthracyclines
Dexrazoxane may leads to lower clinical heart failure and subclinical myocardial dysfunction… compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Clinical heart failure and subclinical myocardial dysfunction combined Defined as clinical heart failure (no definition provided) or subclinical myocardial dysfunction defined as decreased LVFS; however, it was stated that toxicity was graded acco... · children with cancer receiving anthracyclines
1 finding from 1 review
Has died · children with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in overall mortality (Reported as number of participants who died) compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Progression‐free survival · children with cancer receiving anthracyclines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response rate Defined as number of complete remissions (no definition of complete remission provided). Best‐case analysis · children with cancer receiving anthracyclines
It is very uncertain whether dexrazoxane changes tumour response rate Defined as number of complete remissions (no… compared with no cardioprotective intervention (very low certainty).
1 finding from 1 review
Tumour response rate Defined as number of complete responses (i.e. disappearance of active Hodgkin lymphoma (gallium negative, ≥ 70% decrease in the sum of the products of the perpendicular diameters of measurable lesions, and negative bone marrow... · children with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in tumour response rate Defined as number of complete responses (i.e.… compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Quality of life · children with cancer receiving anthracyclines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical heart failure and subclinical myocardial dysfunction combined Comparable definitions; see Characteristics of included studies for exact definitions. Available‐case analysis · adults with cancer receiving anthracyclines
Dexrazoxane probably leads to lower clinical heart failure and subclinical myocardial dysfunction… compared with no cardioprotective intervention or placebo (moderate certainty).
2 findings from 1 review
Secondary malignant neoplasms · children with cancer receiving anthracyclines
Dexrazoxane may leads to higher secondary malignant neoplasms Available‐case analysis compared with no cardioprotective intervention (low certainty).
1 finding from 1 review